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1. Introduction
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive imaging technique 
used to quantify microvascular tissue perfusion with the help of a contrast agent (CA) (Ingrisch and Sourbron 
2013). In MRI, a gadolinium-based CA is used most commonly and injected intravenously after the acquisition 
of pre-contrast baseline scans. The CA increases T1 and T2 relaxation rates of surrounding water protons and 
causes signal enhancement in a T1-weighted acquisition. By measuring multiple T1-weighted images during the 
passage of the CA through the tissue of interest, a time-dependent CA concentration can be extracted from the 
signal-time course of each voxel. Besides determining semi-quantitative and descriptive parameters from the 
concentration curves, e.g. time to peak, area under curve, or maximum, quantitative perfusion parameters can 
be obtained by fitting pharmacokinetic (PK) models to the data (Roberts et al 2006, Sourbron and Buckley 2012, 
2013). Popular PK models that characterize CA transport from DCE-MRI data are the classical Tofts model (TM) 
(Tofts 1997), the extended Tofts model and the two compartment exchange model (Sourbron and Buckley 2011).
The standard approach for estimating PK parameters from DCE-MRI data is using non-linear regression to 
determine a maximum likelihood estimator by non-linear least squares (NLLS) analysis (Seber and Wild 2003). 
For this purpose, an optimizing algorithm aims to minimize the sum of squared residuals between model and 
data and yields, if successful, a point estimate of model parameters. The NLLS approach is widely used, and a 
number of software packages provide non-linear regression implementation of a range of PK models (Huang 
et al 2014a, Beuzit et al 2016). Bayesian probabilistic modeling, on the other hand, offers an alternative modeling 
approach within a framework of probability distributions. Briefly, a prior belief about model parameters is for-
mulated as a probability distribution; this allows to incorporate domain expertise, e.g. physical constraints. With 
A Mittermeier et al
Bayesian pharmacokinetic modeling of dynamic contrast-enhanced magnetic resonance imaging: validation and application
Printed in the UK
18NT02
PHMBA7
© 2019 Institute of Physics and Engineering in Medicine
64
Phys. Med. Biol.
PMB
1361-6560
10.1088/1361-6560/ab3a5a
18
1
11
Physics in Medicine & Biology
IOP
17
September
2019
Bayesian pharmacokinetic modeling of dynamic contrast-
enhanced magnetic resonance imaging: validation and application
Andreas Mittermeier1,3 , Birgit Ertl-Wagner1,2, Jens Ricke1, Olaf Dietrich1  and Michael Ingrisch1
1 Department of Radiology, Ludwig-Maximilians-University Hospital Munich, Munich, Germany
2 Department of Medical Imaging, The Hospital for Sick Children, University of Toronto, Toronto, Canada
3 Author to whom any correspondence should be addressed.
E-mail: Andreas.Mittermeier@med.lmu.de
Keywords: Bayesian inference, tracer-kinetic modeling, DCE-MRI, perfusion
Abstract
Tracer-kinetic analysis of dynamic contrast-enhanced magnetic resonance imaging data is commonly 
performed with the well-known Tofts model and nonlinear least squares (NLLS) regression. This 
approach yields point estimates of model parameters, uncertainty of these estimates can be assessed e.g. 
by an additional bootstrapping analysis. Here, we present a Bayesian probabilistic modeling approach 
for tracer-kinetic analysis with a Tofts model, which yields posterior probability distributions of 
perfusion parameters and therefore promises a robust and information-enriched alternative based on a 
framework of probability distributions. In this manuscript, we use the quantitative imaging biomarkers 
alliance (QIBA) Tofts phantom to evaluate the Bayesian tofts model (BTM) against a bootstrapped 
NLLS approach. Furthermore, we demonstrate how Bayesian posterior probability distributions can be 
employed to assess treatment response in a breast cancer DCE-MRI dataset using Cohen’s d. Accuracy 
and precision of the BTM posterior distributions were validated and found to be in good agreement 
with the NLLS approaches, and assessment of therapy response with respect to uncertainty in 
parameter estimates was found to be excellent. In conclusion, the Bayesian modeling approach provides 
an elegant means to determine uncertainty via posterior distributions within a single step and provides 
honest information about changes in parameter estimates.
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dedicated algorithms, this prior belief is then updated with the measured data and yields the posterior probabil-
ity distributions of the parameters given the data (McElreath 2015). Through recent algorithmic developments 
(Hoffman and Gelman 2011) and the increasing availability of computational power, the use of Bayesian mod-
eling approaches is spreading in various disciplines and has already shown to be a robust and accurate alternative 
for the analysis of MR imaging data (Schmid et al 2006, Orton et al 2007, Woolrich et al 2009, Dikaios et al 2017, 
Tietze et al 2018, Hansen et al 2019). The posterior probability distributions that result from Bayesian modeling 
greatly increase the interpretability of analysis results. Compared to simple point estimates, entire parameter 
probability distributions allow a straightforward assessment of, e.g. whether a parameter has truly changed in the 
course of a therapy, or whether the parameter change has only occurred within the uncertainty of the estimation 
(Shukla-Dave et al 2018).
In the present manuscript, we investigated Bayesian tracer-kinetic modeling in the context of DCE-MRI. 
To this end, we implemented a Bayesian TM (BTM) with the purpose to (i) evaluate accuracy against a NLLS 
approach using a digital reference object, (ii) validate uncertainty estimates against a bootstrapped NLLS 
approach to assess the precision and (iii) demonstrate how Bayesian posterior probability distributions can be 
used to assess treatment response in a breast cancer DCE-MRI dataset.
2. Materials and methods
2.1. Signal conversion and pharmacokinetic models
In a typical DCE-MRI experiment, time-resolved signal intensity curves S(t) are extracted voxel-wise from 
multiple T1-weighted images. To derive quantitative information, the measured signal intensities need to be 
converted to CA concentration curves. For this purpose, the signal equation for the spoiled gradient echo (SPGR) 
sequence in steady state can be used with the baseline signal S0(t), flip angle α, repetition time TR and relaxation 
rate R1(t) as:
S(t) = S0 sin(α)
1− e−TRR1(t)
1− cos(α)e−TRR1(t) . (1)
One can solve equation (1) for the time-dependent relaxation rate R1(t):
R1(t) = − 1
TR
log
(
1− A
1− cos(α)A
)
, (2)
with the auxiliary variable
A =
S(t)
S0
1− e−TRR10
1− cos(α)e−TRR10 . (3)
A time-dependent concentration can then be calculated from the linear relation to the change in relaxation rates 
during and before administration of CA, R1(t) and R10, respectively:
c(t) = (R1(t)− R10)/r1, (4)
with the specific relaxivity of the gadolinium-based CA r1 (Pintaske et al 2006).
A standard approach for the analysis of concentration-time curves in DCE-MRI data is the TM (Tofts and 
Kermode 1991, Tofts 1997, Sourbron and Buckley 2011) which assumes a negligible amount of intravascular 
tracer and describes CA transportation as:
ct(t) = K
transe−tkep ∗ cp(t). (5)
Here, ct(t) is the time-dependent concentrations of CA in the tissue of interest; cp (t) is the concentration in the 
blood plasma of the tissue-feeding artery, often referred to as arterial input function (AIF). ct(t) and cp (t) are 
connected with a convolution, expressed as ‘∗’. The parameter ve  is the volume fraction of the interstitium, the 
extravascular extracellular space (EES). K trans is defined as the transfer constant of CA between blood plasma and 
EES. The rate constant kep = K trans/ve is the ratio of the transfer constant to the EES (Tofts et al 1999, Sourbron 
and Buckley 2011).
The tissue concentration ct(t) can be calculated from the measured signal S(t) with equations (1)–(4) using 
the relaxation time T10 in tissue via R10 = 1/T10. Plasma concentration cp (t) in the AIF can be calculated likewise 
using the relaxation time T10 of blood and the additional transformation from blood to plasma concentration via 
the hematocrit hct:
cp(t) = cb(t) · (1 − hct). (6)
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The standard TM is used in the following within a classical NLLS likelihood framework and a Bayesian frame-
work to quantify perfusion in simulated and measured DCE-MRI data. To account for noise in any observed 
data, an error term is added to the TM from equation (5) and an observation i is given as
yi = ct(ti, θ) + i (7)
where the model parameters K trans and ve  are summarized in the vector θ.
2.2. Data
2.2.1. Validation: QIBA DCE-MRI phantom
To evaluate accuracy of estimates and compare results of different fitting approaches, a simulated phantom 
with known PK parameters was investigated first. The quantitative imaging biomarkers alliance (QIBA)3 
provides several freely available test images for DCE-MRI analysis, known as digital reference objects (DRO). 
These have been used previously to validate various fitting algorithms and analysis toolkits (Ortuño et al 2013, 
Smith et al 2015, Debus et al 2019). The noise-free QIBA_v6_Tofts version was chosen here. The DRO contains 
simulated DCE-MRI data generated with the standard TM in equation (5) for a study duration of t  =  660 s with 
a temporal resolution ∆t = 0.5 s. Tissue concentration-time curves ct(t) have been created for all combinations 
of K trans ∈ {0.01,0.02,0.05,0.1,0.2,0.35} min−1 and ve ∈ {0.01,0.05,0.1,0.2,0.5}, filling a 10×10 pixel patch 
for each combination. Table 1 lists the parameters stated in the QIBA description4, following QIBA’s DCE 
MRI quantification profile5 to convert signal intensities to concentrations (compare equations (1)–(4)). For 
a more realistic setting, complex Gaussian noise with standard deviation σ = 0.2 relative to the pre-contrast 
baseline signal S0 was added to the original noise-free test data. No noise was added to the AIF for simplicity and 
to be able to reliably relate our results to published work of Smith et al (2015) and Ortuño et al (2013). Figure 1 
shows a snapshot of the DRO signal intensities at t  =  100s, the AIF and an exemplary voxel with parameters 
K trans = 0.2 min−1 and ve = 0.2, respectively.
2.2.2. Application: breast cancer DCE-MRI data
The quantitative imaging network (QIN) aims at improving quantitative imaging and does so by sharing data 
which was acquired as part of various QIN studies, collected in the cancer imaging archive (TCIA)6 (Clark et al 
2013). A set of breast cancer DCE-MRI data (Huang et al 2014b) in DICOM format acquired from 10 patients was 
used to demonstrate the performance of the BTM on clinical data. The dataset contains DCE-MRI measurements 
acquired before (visit 1) and during (visit 2) preoperative neoadjuvant chemotherapy (NACT), respectively. For 
three patients, pathologic complete response (pCR) was reported, the remaining seven patients were classified 
as non-pCR. In addition, the dataset includes a region of interest (ROI) per patient, drawn by an experienced 
breast radiologist. A sample-averaged AIF is provided as blood concentration cb(t) and was converted to plasma 
concentration cp (t) using equation (6). Signal intensities within the ROI were converted to tissue concentrations 
using equations (1)–(4). Parameters for the conversion are specified in table 1, further details can be found in the 
original work by Huang et al (2014a).
2.3. Models and analysis
2.3.1. Non-linear least squares approach with bootstrapping
The standard evaluation of DCE-MRI data is performed in a likelihood framework by fitting a non-linear 
regression model to the concentration-time curve in every voxel. The NLLS approach minimizes the sum 
of squared errors between measured data y i at timepoint ti for i = 0, 1, ...,N  and the model function ct(ti) in 
equation (7)
Table 1. Parameters for the conversion from signal to concentration.
T10 (Tissue) T10 (Blood) (ms) r1 (Lmmol−1 ms−1) α (°) TR (ms) TE hct
QIBA DROa 1000 ms 1440 0.0045 30 5 — 0.45
QIN breastb 1666 msc 1440 0.0045 10 6.2 2.9 ms 0.45
a Quantitative imaging biomarker alliance digital reference object QIBA_v6_Tofts.
b Quantitative imaging network breast cancer dataset.
c Personal communication with the author of Huang et al (2014a).
3 https://sites.duke.edu/dblab/qibacontent/
4 https://sites.duke.edu/dblab/files/2015/05/Dynamic_v6_beta1_description_Rev1.pdf
5 http://qibawiki.rsna.org/images/1/12/DCE-MRI_Quantification_Profile_v1.0.pdf
6 https://wiki.cancerimagingarchive.net/display/Public/Collections
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min
N∑
i=0
(yi − ct(ti, θ))2 = min
N∑
i=0
2i (8)
to infer the best guess parameter θˆ. Assuming normally distributed noise i, the least-squares estimator θˆ equals 
the maximum-likelihood estimator (Seber and Wild 2003).
An implementation of the Broyden–Fletcher–Goldberg–Shano (L-BFGS) algorithm (Byrd et al 1994, Zhu 
et al 1997) in SciPy7 (Jones et al 2001) was used for inference of the parameters via the optimize.minimize func-
tion. Initial values for K trans and ve  were set to 0.001; constraints for K trans and ve  were set to positivity and [0,1], 
respectively.The concentration curves of the DRO were then fitted and parameter maps were constructed 
for K trans and ve . By comparing them to the true parameter maps, percentage error maps were calculated as 
θ%err = (θˆ − θtrue)/θtrue.
A bootstrap method was implemented to assess the uncertainty of θˆ (Kershaw and Buckley 2006). For that, 
the residuals, i.e. the difference between the fitted and the measured curve were calculated. In a next step, the 
residuals were resampled by randomly drawing samples with replacement. Subsequently, the resampled residu-
als were added to the fitted curve and the TM was used to determine another set of estimates, equivalent to infer-
ring the original best guess. The number of iterations was set to 1000.
Uncertainty maps were then calculated from the bootstrap samples for the NLLS approach. Denoted as σ, 
half the width between 17th and 83rd percentile was considered a more robust measure for the precision than the 
standard deviation and is used throughout this work. For samples following a Gaussian normal distribution, σ 
would be equal to the standard deviation.
2.3.2. Bayesian inference and implementation
The alternative evaluation is performed in a Bayesian framework which infers a full posterior distribution P(θ | y) 
of the model parameters θ given an observation of data y . The observational error i for each measurement y i at 
timepoint ti for i = 0, 1, ...,N  in equation (7) is assumed to be Gaussian with standard deviation σ. Hence, the joint 
observations of CA concentration in each voxel, conditional on the parameters, are modeled in the likelihood as
P(y | θ) =
N∏
i=0
N (yi | ct(ti, θ),σ2), (9)
with N  representing a normal distribution and ct(ti, θ) the CA tissue concentration evaluated with the TM in 
equation (5).
Information about the parameters prior to the observation of data are specified in the prior distribution P(θ), 
enforcing physical or biological constraints. The likelihood of the data P(y | θ) and the product of the prior prob-
ability densities P(θ) are combined with the observed data to infer the joint posterior distribution via Bayes’ 
theorem:
P(θ | y) = P(y | θ) P(θ)
P(y)
. (10)
The denominator in equation (10) is referred to as model evidence and calculates as P(y) =
∫
P(θ)P(y | θ)dθ. 
If the complexity of the model allows no analytical solution to this integral, Markov Chain Monte Carlo (MCMC) 
Figure 1. (a) Snapshot of the QIBA_v6_Tofts DRO at t  =  100 s; the AIF is the bottom strip of the image, maximum of the AIF with 
timepoint labels in seconds are the top left strip and the zero patch (K trans = 0.0 min−1, ve = 0.5) is the top right strip. Intensity-time 
curves for AIF (b) and one pixel with K trans = 0.2 min−1 and ve = 0.2 with added noise (c), respectively.
7 Python 3.6.6, scipy 1.1.0, www.scipy.org/
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methods (Gilks et al 1995) offer a means to determine the posterior probability distribution. Briefly, a MCMC 
algorithm draws samples from a target distribution, which equals the desired posterior distribution. The accepted 
parameter proposals are stored in a chain or trace of estimates (Kruschke 2014).
The BTM was implemented in Stan (Carpenter et al 2017), an open-source software package, using pystan8. In 
the present analysis, weakly informative priors were chosen which are applicable to a wide range of clinical DCE-
MRI data without restrictions. Appendix provides a prior predictive check on these distributions, showing their 
weakly informative nature by comparing generated concentration curves with real observations. In particular, 
for the volume fraction ve ∈ [0, 1] a beta prior ve ∼ Beta(α = 2,β = 2) was chosen and for K trans ∈ R+ a gamma 
prior was specified K trans(min−1) ∼ Gamma(α = 1.1,β = 1/0.002). The prior for the standard deviation of 
the observational error was set to σ(mmol/L) ∼ LogNormal(µ = 0,σ = 1). MCMC samples were drawn from 
the posterior distribution with the No-U-Turn (NUTS) algorithm (Hoffman and Gelman 2011). The number of 
iterations was set to 1000, sampled in two chains simultaneously, following a warm-up period of 500 iterations. 
Stan also reports divergences of the sampling algorithm and indicates the need to update the default settings of 
NUTS, e.g. initial step size and target acceptance rate.
To monitor the convergence of the MCMC chains to the target distribution, different diagnostics are auto-
matically run alongside in Stan. The potential scale reduction statistic, Rˆ, by Gelman and Rubin (1992) compares 
the sample variance within and across chains, and indicates if chains have not converged to a common distribu-
tion (Rˆ > 1.1). The effective sample size Neff indicates the degree of uncertainty in estimates due to autocorrela-
tion of samples (Geyer 2011).
All concentration curves of the DRO were then fitted with the BTM to obtain posterior probability distributions 
of the parameters θ. To be able to compare the distributions to point estimates and to generate parameter maps, two 
hallmarks of the posterior distributions were determined: the median and, as for the bootstrap samples, half the 
distance between the 17th and 83rd percentile, denoted as σ. By comparing the median parameter maps to the true 
parameter maps, a map of the percentage error was calculated as above to assess the accuracy of estimates.
To evaluate the breast cancer DCE-MRI datasets, the mean tissue concentration curve over the ROI ct,ROI(t) 
was calculated for each patient and both visits. Subsequently, all concentration-time curves were fitted with the 
BTM to infer posterior distributions for the model parameters θ. To ensure that the model adequately captured 
the underlying data generating process, a posterior predictive check (PPC) was performed. Briefly, we used the 
BTM to generate new predictive data yˆ and checked if it resembled the observed data. The full posterior distribu-
tion is exploited in this way to generate a posterior predictive distribution
P(yˆ|y) =
∫
P(yˆ|θ)P(θ|y)dθ, (11)
which propagates the uncertainty in the parameter estimates to uncertainty about prediction (Betancourt 2015, 
McElreath 2015, Gabry et al 2017). In this way, PPCs allow to detect systematic modeling errors and violations 
of model assumptions. Subsequently, the posterior distributions of K trans were compared across visits for all 
patients with the objective to discriminate between patients with pCR and non-pCR.
2.4. Statistical analysis
A quantitative statistical measure for signal fidelity is the structural similarity index (SSIM) (Wang et al 2004). 
It gives an average value over similarities of three key elements of an image: luminance, contrast and structure 
(Wang and Bovik 2009). To assess the accuracy of parameter estimates for the DRO, the SSIM was calculated 
between the estimated and the true parameter maps. As a comparison, the root-mean-squared error (RMSE) 
was calculated alongside. In order to get reasonable values for RMSE, outliers in K trans-estimates obtained from 
NLLS fitting needed to be restricted to one. In addition, the SSIM was calculated between the σ-uncertainty maps 
determined with the BTM and the bootstrapping method to assess similarities in the precision of estimates.
To compare the K trans posterior distributions between visits for the breast cancer DCE-MRI dataset, Cohen’s 
d was calculated for each of the ten patients as:
d =
x¯1 − x¯2√
(σ21 + σ
2
2)/2
. (12)
x¯ represents the average K trans value per visit, σ its standard deviation. In this way, the width of the posterior 
distributions are incorporated into a single value. Compared to just reporting the percentage change of K trans  
mean values, the uncertainty in parameter estimation is accounted for. An univariate logistic regression (ULR) 
model, implemented in scikit-learn9 (Pedregosa et al 2011), was fitted to the Cohen’s d values. The receiver 
operating characteristic (ROC) area under curve (AUC) was calculated in order to obtain a quantitative measure 
for the assessment of response.
8 Python 3.6.6, pystan 2.18.0, https://pystan.readthedocs.io/
9 Python 3.6.6, scikit-learn 0.20.0, https://scikit-learn.org/
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3. Results
3.1. Validation: QIBA DCE-MRI phantom
Concentration-time curves of the DRO were evaluated within a Bayesian and likelihood framework. The 
resulting parameter estimates for K trans are exemplarily shown in figure 2 for the Bayesian approach (a) and 
the NLLS reference (d). Note that the voxels in the Bayesian framework show median values of their respective 
posterior distributions while voxels in the likelihood framework represent point estimates. In general, the 
parameter maps show high accordance with the true values. The corresponding percentage error maps in the 
middle column (b) and (e) display relatively low errors for all regions with ve > 0.01 for both methods. Low 
accuracy, hence high percentage errors are observed for regions where ve = 0.01. SSIM between estimated and 
true K trans-maps is higher for the BTM than for the NLLS approach. Furthermore, RMSE is lower for the BTM for 
both PK parameter maps. Details are provided in table 2.
The right column of figure 2 displays the precision of the parameter estimates evaluated with the BTM (c) and 
a bootstrapping method applied to the fit results of the NLLS approach (f). The visual analysis of the uncertainty 
maps reveals very similar patterns for both approaches, supported by a SSIM of 91%. The highest uncertainty 
occurs in regions with the highest percentage error for the fitting parameter estimates. The remaining parameter 
combinations have much greater precision. Information about divergences (BTM) and pixels where the NLLS 
algorithm did not find a solution can be found in table 3, together with computational times for fitting all 3000 
pixels with BTM and NLLS approaches and the additional bootstrap analysis.
3.2. Application: breast cancer DCE-MRI data
Figure 3 shows representative signal intensity-time curves with the associated PPCs (a)–(c) and their 
corresponding K trans posterior distributions (d). Here, the dark line illustrates the median and the increasingly 
lighter bands are the 20%, 40%, 60% and 80% highest density intervals (HDI) between the corresponding 
(0.4,0.6), (0.3,0.7), (0.2,0.8) and (0.1,0.9) percentiles of the posterior predictive distribution. The PPC in (a) 
Figure 2. Estimated K trans  with BTM (top) and NLLS approach (bottom). The left column displays median (a) and point estimates 
(d). The middle column ((b) and (e)) shows the calculated percentage error between estimates and ground truth. The right column 
illustrates the uncertainty σ of the Bayesian posterior (c) and the additional bootstrap samples (f).
Table 2. SSIM and RMSE between estimated DRO K trans  and ve  parameter maps and ground truth for both approaches; SSIM of 100% 
indicates perfect similarity.
K trans ve
BTM (%) NLLS (%) BTM (%) NLLS (%)
SSIM 96 91 92 94
RMSE 2.5 7.0 4.1 5.4
BTM  =  Bayesian tofts model; NLLS  =  Non-linear least squares approach; SSIM  =  Structural similarity index; RMSE  =  Root-mean-
squared error.
Phys. Med. Biol. 64 (2019) 18NT02 (11pp)
7A Mittermeier et al
indicates a good fit of the model to the data, the corresponding posterior distribution (green) for K trans is narrow. 
The PPC in (b) suggests that the chosen model provides a good fit to the data, the high noise level in the data is 
associated with a broader posterior distribution (orange). In (c), the noise level of the data is comparable to (a), 
however the PPC indicates a modeling error.
Figure 4 shows the posterior distributions of K trans for all patients for visit 1 (blue) and visit 2 (orange), 
before and during NACT, respectively. With one exception, a general decrease in K trans is observed. The degree 
Table 3. Fitting process and parameter estimation of all 50×60 DRO concentration curves.
BTM NLLS
Divergences 17 27
Computational time: fitting ∼48 min ∼2 min
Computational time: uncertainty included ∼2100 mina
BTM  =  Bayesian tofts model; NLLS  =  Non-linear least squares approach.
a Based on additional bootstrap analysis.
Figure 3. Observed signal intensity-time courses (dots) with posterior predictive distribution median (line) and the 20%, 40%, 
60% and 80% highest density intervals (HDI); (a) for a good fit to data with low noise level, (b) for a good fit to data with high noise 
level, and (c) for a bad fit to data with low noise level. (d) Posterior distributions for K trans  estimated from the respective signal 
intensity-time curves (color-coded).
Figure 4. Posterior probability densities of K trans  for all patients. Blue corresponds to visit 1, orange to visit 2. BC05, BC06 and BC15 
are labeled pCR, the rest non-pCR.
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of change, dependent on the width of the posterior distributions, is summarized in Cohen’s d values and visual-
ized in figure 5; light-gray represents non-pCR, dark-gray pCR. The ULR analysis revealed a ROC AUC of 0.952. 
Computational time for fitting all 20 ROI-averaged concentration curves was  ∼20 s for the BTM.
4. Discussion
In this study, we assessed posterior probability distributions of tracer-kinetic parameters obtained with a BTM 
against a standard NLLS approach. Validation with a DRO revealed high accuracy of BTM and NLLS approaches, 
indicated by strong similarity between estimated and ground truth maps. In addition, precision of estimates, 
assessed via the width of the posterior probability distributions and bootstrapping, respectively, was in very good 
agreement between both approaches. Analysis of the breast cancer DCE-MRI dataset with the BTM revealed 
that the degree of decrease in K trans gives information about the pathologic response to NACT. The response 
in dependence of the uncertainty of parameter estimates was quantified with Cohen’s d, calculated from the 
posterior distributions between visit 1 and 2. ULR modeling indicated excellent prediction of response.
Concerning the analysis of the DRO with the BTM, median parameter estimates were compared to the ground 
truth to assess the accuracy, otherwise not available with measured data. It was found that the Bayesian estimates 
generally have a very strong similarity with the ground truth, validating the accuracy of our BTM. The recovered 
parameters also have complementary regions of high and low percentage errors compared to the established 
NLLS fitting routine. RMS errors were lower for both implementations in the present work compared to similar 
DRO analysis by Smith et al (2015) and Ortuño et al (2013). Albeit, the results are in good comparison. Caution is 
still required for voxels with low ve . Concentration curves with these parameter combinations have very limited 
intensity changes which practically vanish in the added background noise.
The variance of estimates inherent in the Bayesian posterior distribution was compared to a bootstrapping 
error analysis, performed likewise to the work of Kershaw and Buckley (2006). It was demonstrated that the 
uncertainty maps of the BTM resemble those calculated with the bootstrap analysis, validating the precision 
of parameters recovered with the BTM. To the best of our knowledge, only (Schmid et al 2006) implemented a 
Bayesian PK model with the objective to make use of the posterior probability distribution. Parts of the present 
study build up on their work and go beyond by capturing even more information from the posterior distribution. 
Their approach was applied to patient data only, whereas in the present work, accuracy and precision of estimates 
were validated with a digital phantom first.
Furthermore, we applied the BTM to the breast cancer DCE-MRI data, performed PPCs and investigated 
the posterior distributions. For a PPC, the observed data was compared to the posterior predictive distribution, 
illustrated as percentile intervals of highest density. A good fit to the data results in a posterior distribution which 
reflects the noise level in the data; low noise corresponds to a narrow posterior and vice versa. However, a bad fit 
to the data results in a broad posterior distribution despite a low noise level. This indicates a systematic modeling 
error which influences the information we gained about uncertainty. More complex PK models which incor-
porate additional assumptions about CA transport, e.g. the extended Tofts model, could be able to produce a 
better fit to certain data. Hence, assessing posterior distributions requires to check the corresponding data and fit 
before drawing any conclusions from it. While feasible for ROI-based analysis with only a handful of concentra-
tion curves, visual assessment is not possible in a pixelwise analysis. However, this can be necessary considering 
that tumorous tissue can be very heterogeneous (Wu et al 2018). An automated Bayesian model selection step as 
proposed in the work of Duan et al (2017) could be an effective means to reduce systematic modeling error but is 
beyond the scope of this study.
Figure 5. Cohen’s d calculated from K trans  posterior distributions for all patients; sorted by value.
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In order to assess therapy response for the patients in the breast cancer DCE-MRI dataset, Huang et al (2014a) 
showed in their original work that using visit 2 K trans or the percentage change of K trans between visits as metrics 
yields good to excellent results. However, the uncertainty in estimating PK parameters with tracer-kinetic models 
is not accounted for. For this purpose, we calculated Cohen’s d as a means of quantitative change in parameter 
estimates which depends on the precision of estimates. In contrast, the authors of Schmid et al (2006) used the 
posterior distributions in each voxel to apply probabilistic thresholding, and then compared the mean values 
of K trans between visits. Using Cohen’s d metric, the assessment of response was found to be excellent by means 
of an ULR analysis. Considering the findings of the PPCs, including a model selection step as explained above 
could decrease the influence of systematic modeling errors on posterior distributions and hence Cohen’s d val-
ues which may further improve assessment of therapy response.
Limitations of the present work include large computational time when fitting the BTM to the DRO-data. On 
the one hand, the MCMC sampling is time and memory consuming but necessary to avoid divergences. On the 
other hand, it yields a full posterior probability distribution with information about the uncertainty, and obtain-
ing the same information with a bootstrap analysis of a NLLS fit requires even more computation time. Further-
more, the simulated DRO curves have a much higher time-resolution compared to measured data. Evaluating 
real DCE-MRI data increases the speed of the analysis greatly. Moreover, the influence of the chosen prior distri-
butions on the results was not assessed in the present study.
In conclusion, we evaluated a BTM with a DRO, assessed accuracy and precision against the standard NLLS 
approach and showed how posterior distributions are used to assess therapy response. We demonstrated that 
Bayesian modeling provides an elegant means to assess posterior probability distributions, which are in good 
agreement with established approaches.
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Appendix. Prior predictive check
To assess if the choice of prior distributions for the model parameters covers a reasonable range of concentration-
time curves, it is useful to perform a prior predictive check. For this purpose, we generated 100 000 MCMC samples 
from the prior predictive distribution,
Figure A1. Prior probability density functions for K trans  (a), ve  (b), σ (c) and the subsequent prior predictive check (d). Simulated 
concentration-time curves (dots) for each parameter combination of the QIBA phantom are overlaid on the prior predictive 
distribution; illustrated by median (line) and the 20%–80% highest density intervals (HDI).
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P(yˆ) =
∫
P(yˆ | θ) P(θ)dθ, (A.1)
only considering the prior distributions without any actual data. This quantifies the range of possible 
observations yˆ, predicted by our model. In a prior predictive check, the predicted data is compared to real 
observations and the extent of extreme observations indicates the level of disagreement between domain 
expertise and model assumptions. Figure A1 shows the probability density functions of the chosen priors (a)–(c) 
and the prior predictive check (d). The black dots are actual observed data from the QIBA phantom, one curve 
for each parameter combination of K trans and ve , to assess the scope of possible phantom curves. The increasingly 
lighter green bands represent the 20%, 40%, 60% and 80% highest density intervals between the corresponding 
percentiles of the prior predictive distribution; the green line is the median thereof. We find that the model 
predicts observations that are more extreme than the phantom data but not too extreme to be unrealistic given 
the assumed observational error. Hence, we conclude that the chosen prior distributions are reasonable and 
weakly informative.
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